Ondansetron and Dotarem drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ondansetron (ondansetron) and Dotarem (gadoterate meglumine). Common drug interactions include cytokine release syndrome among females and abscess limb among males.

The phase IV clinical study analyzes what interactions people have when they take Ondansetron and Dotarem. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Ondansetron?

Ondansetron has active ingredients of ondansetron. It is often used in nausea. eHealthMe is studying from 122,738 Ondansetron users. Check the latest studies of Ondansetron.

What is Dotarem?

Dotarem has active ingredients of gadoterate meglumine. eHealthMe is studying from 2,749 Dotarem users. Check the latest studies of Dotarem.

On Jul, 28, 2026

19 people who take Ondansetron and Dotarem together, and have interactions are studied.

Ondansetron and Dotarem drug interactions.

What are the common drug interactions of Ondansetron and Dotarem, by gender? *:

female:

Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Dysarthria (speech disorder)
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Bone pain
Herpes zoster
Wound infection
Acute respiratory failure
Anaphylactic reaction (serious allergic reaction)

male:

Abscess limb (limb infection)
Injection site extravasation (flow of (blood or lymph) from injection site)
Pain in extremity
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)

What are the common drug interactions of Ondansetron and Dotarem, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Dysarthria (speech disorder)

10-19:

Bone pain
Herpes zoster

20-29:

Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)

30-39:

Seizure (abnormal excessive or synchronous neuronal activity in the brain)

40-49:

Injection site extravasation (flow of (blood or lymph) from injection site)
Pain in extremity

50-59:

Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)

60+:

Wound infection
Abscess limb (limb infection)
Acute respiratory failure
Anaphylactic reaction (serious allergic reaction)

What are the existing conditions these people have? *

Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 10 people, 52.63%
Constipation: 10 people, 52.63%
Stress And Anxiety: 10 people, 52.63%
Nausea And Vomiting: 10 people, 52.63%
Oral Herpes (viral infection of mouth): 9 people, 47.37%
Birth Control: 9 people, 47.37%
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 9 people, 47.37%
Pain In Extremity: 9 people, 47.37%
Pain: 2 people, 10.53%
Bone Marrow Conditioning Regimen: 2 people, 10.53%

* Approximation only. Some reports may have incomplete information.

Do you take Ondansetron and Dotarem?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously